-
Article
Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up
Specific recommendations on screening modalities for paraganglioma (PGL) and phaeochromocytoma (PCC) in asymptomatic SDHx mutation carriers (relatives) are still lacking. We evaluated the added value of 18F-FDG P...
-
Article
Caractérisation des tumeurs neuroendocrines digestives ou thoraciques
Once the diagnosis of a neuroendocrine tumour has been made, characterisation is an essential step before therapy. It comes before the decision regarding treatment is made. This requires a multidisciplinary te...
-
Article
Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
The prognosis of advanced adrenocortical carcinoma (ACC) is dismal but heterogeneous. In 2011, mitotane is the only drug approved in Europe and US for the treatment of advanced ACC. Mitotane exerts both antise...
-
Article
Le cancer de la surrénale. Comment optimiser la prise en charge d’un cancer rare? UPC Inca, COMETE
Adrenal cancers (adrenal cortical carcinoma, malignant pheochromocytoma and paraganglioma) are rare tumours that may occur as a familial disease. Medical treatments did not show any efficiency in the managemen...
-
Chapter
Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP): facteurs pronostiques
Ce chapitre fait le point sur les facteurs pronostiques des tumeurs endocrines gastro-entéro-pancréatiques (TE GEP) non à petites cellules (1, 2). Nous utiliserons le terme de « tumeur endocrine », pour définir d...
-
Chapter
Chimiothérapie des tumeurs endocrines
Le rôle des traitements médicaux dans la prise en charge des tumeurs endocrines digestives et pancréatiques (TE) est double : il s’agit d’obtenir un contrôle tumoral et un contrôle des sécrétions hormonales. E...
-
Chapter
Tumeurs endocrines gastro-entéro-pancréatiques (TE GEP). Classifications, présentations cliniques, marqueurs biologiques
Ce chapitre fait le point sur les classifications, les modalités du diagnostic clinique, le bilan biologique des tumeurs endocrines gastro-entéro-pancréatiques (TE GEP) non à petites cellules (1–5). Nous utili...
-
Article
Intérêt de la mesure individualisée de la qualité de vie en oncologie: utilisation du SEIQoL chez des patients traités pour tumeur neuro-endocrine
Les mesures individualisées de qualité de vie en oncologie peuvent apporter des informations spécifiques et complémentaires à celles qui sont issues des mesures standardisées de qualité de vie. Cet article ill...
-
Article
Open AccessLong-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging
Imaging-detected relapses are observed in a significant proportion of patients with medullary thyroid carcinoma (MTC) with normal postoperative imaging studies. The aim of this study was to search for prognost...
-
Article
Open AccessChromogranin A and the α-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma
Using specific immunoradiometric assays, we evaluated the clinical usefulness of chromogranin A and the α-subunit of glycoprotein hormones in neuroendocrine tumours of neuroectodermic origin. The serum α-subun...
-
Article
Open AccessTreatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations ...
-
Article
Open AccessTreatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a...
-
Article
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours
Circulating neuron-specific enolase (NSE) and chromogranin A (CgA) were measured in 128 patients with neuroendocrine tumours (NET) to compare their sensitivity and specificity, to investigate factors associate...
-
Article
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic the...
